Urokinase infusion for severe XXXX .

@entity1 @entity10 @entity1276 @entity548
The purpose of this study was to explore in @entity1 with intraventricular haematomas the effectiveness and complication rate of a treatment protocol including standard ventriculostomy and application of urokinase via the catheter. Our series includes 16 @entity1 with severe CT-diagnosed intraparenchymal and predominantly intraventricular @entity548 . In all cases, ventricular drainage was performed. Urokinase treatment was started immediately with intraventricular infusions of 10,000 U urokinase in 5 ml sterile physiological saline every 12 hours. Twelve @entity1 had an excellent outcome, three good and one poor. There were no complications related to urokinase therapy. Side effects of the infusion volume were profuse sweating and @entity10 which were present at 10 ml total infusion volume, but disappeared after reduction to 5 ml. A group of five @entity1 with comparable lesions treated only with ventriculostomy served as controls. Two of them had a good outcome, two a poor one and one died. The late results in the urokinase-treated group were also favourable. Only one of the @entity1 developed @entity1276 and was shunted. In the control group, two @entity1 required shunting for delayed @entity1276 . We conclude that this protocol for urokinase treatment is safe and effective and can be used in almost all @entity1 with @entity548 .
